Common stock, $0.001 par value per share
- Symbol
- RLMD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Relmada Therapeutics, Inc.
RLMDNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 28, 2026, Relmada Therapeutics, Inc. (the “Company”), issued a press release announcing the appointment of Bipin Dalmia, PhD, MBA as the Company’s Chief Business. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1.…
Press release in this filing
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer →Company context
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
Current securities
Registered securities in this filing
RELMADA THERAPEUTICS, INC. · 8-K · Filed 2026-07-28
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On July 28, 2026, Relmada
Therapeutics, Inc. (the “Company”), issued a press release announcing the appointment of Bipin Dalmia, PhD, MBA as the Company’s
Chief Business. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1.
The information set
forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities
Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 2 ea029944901ex99-1.htm PRESS RELEASE ISSUED ON JULY 28, 2026 Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation. CORAL GABLES, FL - July 28, 2026 (GlobeNewswire) - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada’s corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa. Bipin Dalmia joins Relmada with nearly three decades of biopharmaceutical leadership, combining extensive experience in corporate strategy and business development with deep expertise in non-muscle invasive bladder cancer (NMIBC). As the Company advances NDV-01, its novel sustained-release intravesical therapy for patients with …
Open exhibit ↗